Slide 1: Q4'23 Earnings Presentation
Enabling discovery, safety and production of tomorrow’s therapeutics NASDAQ: HBIO Q4’23 Earnings Presentation Jim Green, Chairman, President & CEO Jennifer Cote, CFO & Treasurer March 7, 2024
Slide 2: Forward-Looking Statements and Non-GAAP Financial Information
Forward-Looking Statements and Non-GAAP Financial Information Forward-Looking Statements This document contains forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified b
Slide 3: CEO Summary: Q4'23 Highlights
CEO Summary: Q4’23 Highlights Growth in Americas offset by post-Covid-19 Academic funding from China Income Statement Components Q4' 2023 Q4' 2022 Revenue (GAAP) 28.2 28.4 Growth Rate -1.0% Favorable FX Impact 0.4 Net Reduction in Discontinued Products (0.9) Gross Margin 16.3 15.8 % of Revenue 58.0%
Slide 4: Q4'23 Revenue: Americas Solid, Impacted by Reduced China Funding
Q4’23 Revenue: Americas Solid, Impacted by Reduced China Funding Fx Adjustment As Reported (in $M) Q4'23 Q4'22 CMT $ 12.8 $ 14.0 -8.4% Pre-Clinical $ 14.9 $ 14.4 3.4% Currency* $ 0.4 1.4% Total $ 28.2 $ 28.4 -1.0% Americas EMEA APAC • Overall: Up 4.1% as reported, includes 2.1% • Overall: Up 3.1% as
Slide 5: New Product Introductions: Focused on Commercialization
New Product Introductions: Focused on Commercialization EXPAND HIGH EXPAND TO BIO- STRENGTHEN THE BASE INNOVATE CELLULAR VOLUME APPICATIONS PRODUCTION PRECLINICAL PRECLINICAL CMT CMT- ORGANOIDS • Introduced SoHo Shared • Introduced VivaMARS • Established commercial • Launched the Mesh MEA Housing Te
Slide 6: Financials
6 Financials 6
Slide 7: Q4'23 Performance versus Q4'22 (GAAP except where noted)
Q4’23 Performance versus Q4’22 (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $3.6 $3.7 Q4’23 Revenue includes $0.1 million and Q4’22 includes $1.0 million in sales of discontinued products (LOSS) EARNINGS PER SHARE CASH FLOW FROM OPERATIONS NET DEBT*
Slide 8: FY23 Performance versus FY22 (GAAP except where noted)
FY23 Performance versus FY22 (GAAP except where noted) $ Million except REVENUE ADJUSTED EBITDA* per share data GROSS MARGIN $14.6 $10.8 FY23 Revenue includes $0.5 million and FY22 includes $5.5 million in sales of discontinued products (LOSS) EARNINGS PER SHARE CASH FLOW FROM OPERATIONS NET DEBT* F
Slide 9: Outlook
9 Outlook 9
Slide 10: 2024 Full Year Outlook: 'A Tale of Two Halves'
2024 Full Year Outlook: ‘A Tale of Two Halves’ For FY2024, we expect: ▪ Flat to modest revenue growth for the full year ▪ Weakness in the first half versus a strong prior year comparison ▪ Strong second half growth versus both first half of 2024 and versus the second half of 2023, supported by new p
Slide 11: Appendix
11 Appendix
Slide 12: Reconciliation to GAAP P&L
12 Reconciliation to GAAP P&L 12 12
Slide 13: Slide 13